Acrivon Therapeutics Inc.... (ACRV)
| Bid | 4.8 |
| Market Cap | 167.98M |
| Revenue (ttm) | 1.54M |
| Net Income (ttm) | -62.9M |
| EPS (ttm) | -2.66 |
| PE Ratio (ttm) | -2.03 |
| Forward PE | -1.88 |
| Analyst | Buy |
| Ask | 5.09 |
| Volume | 36,806 |
| Avg. Volume (20D) | 48,781 |
| Open | 5.55 |
| Previous Close | 5.61 |
| Day's Range | 5.33 - 5.50 |
| 52-Week Range | 4.69 - 11.90 |
| Beta | 0.86 |
About ACRV
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics tha...
Analyst Forecast
According to 6 analyst ratings, the average rating for ACRV stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 252.18% from the latest price.
Stock Forecasts
3 months ago · seekingalpha.com
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent ThesisAcrivon Therapeutics is developing a targeted oncology therapy with a companion proteomics-based signature, showing promising activity in their lead compound for certain patients with gynecologic canc...